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Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is
a public–private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of
vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic
healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies.
Methods: A retrospective dynamic cohort study was conducted through a distributed network approach.
Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years
1990–2000 and influenza-vaccine for birth years 1920–1950 was estimated using period-prevalence and
inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet,
Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers
extracted the data, transformed it into a common structure and ran an R-script locally. The created output
tables were shared and pooled at a central server.
Results: The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons
for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from
84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to
90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth
years 1997–2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-
vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was
roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50%
was observed in Catalonia (Spain).
3244 T. Braeye et al. / Vaccine 38 (2020) 3243–3254Conclusions: We obtained detailed, age-specific coverage estimates though a common procedure. We dis-
cussed between database comparability and comparability to published national estimates.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The impact of a vaccine on the burden of a disease in popula-
tions differs from an assessment in individuals. Because of effects
like herd immunity, the population coverage should be included
in benefit-risk vaccine studies [1]. While several sources such as
surveys, social security data or health insurance claims data [2]
can be used to obtain coverage estimates, electronic healthcare
records (eHR) are likely to gain importance. Their growing impor-
tance as source to rapidly provide evidence on aspects of vaccine
coverage, benefits and risks has multiple reasons: I) eHR are less
likely associated with biases, such as recall or selective sampling
bias, that are important for other sources [3], II) eHR potentially
allow for risk group specific analysis, a necessary feature since vac-
cine recommendations can be risk group specific and III) eHR allow
for age-specific, near real time coverage estimation with a high
positive predictive value at relatively low cost [4–6]. Despite these
advantages, real world applications have reported issues with
incompleteness and misclassification [7–9]. These concerns and
the fact that there are many different kinds of eHR-databases
require a ‘fit for purpose’-assessment prior to their use in
benefit-risk hypothesis testing.
Most European countries produce regional or national vaccine
coverage estimates, but databases and methods used to estimate
vaccination coverage vary widely and comparability is challenging
at an international level [10–12]. Several projects and organisa-
tions, such as the WHO Centralized Information System for Infec-
tious Diseases (CISID) [13] and Vaccine European New Integrated
Collaboration Effort (VENICE) [14] aim to improve the quality
and comparability of vaccine coverage estimation by defining
and implementing standards. These projects have been in place
for several years and have established robust databases. An alter-
native approach to obtain comparable coverage estimates from
multiple countries is the standardized collection of data using sur-
veys [15,16]. The ADVANCE project differed from these existing
approaches as we did not require our partners to present coverage
estimates themselves nor did we collect data ourselves. Instead,
participating databases were asked to run a script that transformed
available eHRs into vaccination coverage estimates locally. This
insured that the steps for data cleaning, transformation and analy-
sis were identical between databases. In a previous paper, we
investigated methods to deal with one source of incompleteness
encountered in eHR-databases; unregistered vaccinations because
of incomplete follow-up [17]. From that paper we selected two
methods that take person-time into account when estimating
coverage.
The Accelerated Development of VAccine beNefit-risk Collabora-
tion in Europe (ADVANCE) projectwas a public private collaboration
aiming to develop and test a system for rapid benefit-risk monitor-
ing of vaccines using existing healthcare databases in Europe. For
further reading on the ADVANCE project and its code of conduct
we refer to http://www.advance-vaccines.eu/. Several studies were
conducted to demonstrate the ability to generate evidence on per-
tussis vaccine coverage, benefits and risks [18]. The results pre-
sented here were part of a second round of feasibility assessments
to create readiness to study additional vaccines beyond pertussis.
In this paper we estimated the coverage with measles, HPV and
influenza-vaccines in participating eHR-databases.2. Material and methods
2.1. Design and setting
We conducted a retrospective dynamic cohort study using a
distributed network approach.
2.2. Description of participating databases
Seven European healthcare databases participated in this study
(Table 1). The general characteristics of the databases have been
described in more detail before [19]. All databases comprised elec-
tronic health records. There was a distinction between regional
(BIFAP, SIDIAP, PEDIANET, Val Padana) and national databases
(THIN, RCGP-RSC, SSI/AUH). There was also a distinction between
databases that collected a subset (BIFAP, SIDIAP, PEDIANET, THIN,
RCGP-RSC) or aimed to collect all data (Val Padana, SSI/AUH) from
a given area. In PEDIANET only children whose parents consented
linkage to the Veneto regional vaccination registry were included.
Finally, data was collected mainly from primary care healthcare
services, except for SSI/AUH and Val Padana where linkage
between registries was performed.
2.3. Vaccinations
The vaccines of interest in this assessment comprised measles-
containing vaccines, HPV-vaccines and seasonal influenza vaccines.
Vaccination schedules for these vaccines differed between the
countries included in this study: Denmark, Italy, United Kingdom
and Spain (Table 2). Vaccination information was extracted from
the eHR-databases locally and transformed into a common vacci-
nation file which comprised the following variables: a patient
identifier, a vaccine type (coded as the disease against which the
vaccine protected), Anatomical Therapeutic Chemical (ATC-code,
according to WHO), a brand name, a recorded dose number and/
or a derived dose number (derivation based on age and sequence)
and a date of vaccination. The brand and ATC-code could be left
empty. Val Padana and RCGP-RSC provided a derived dose (derived
from the sequence of observed doses). The other databases pro-
vided a recorded dose. To determine the seasonal influenza vaccine
coverage, we looked at the date of vaccination. For example, an
influenza vaccination registered between 1 July 2010 and 30 June
2011 was included in the 2010/11 seasonal coverage estimation.
2.4. Source and study population
The source population for this assessment comprised all sub-
jects registered in the databases listed above. Each database pro-
vided a start- and end-date of follow-up for each person. Re-
entry into the database, providing several start- or end-dates per
person, was not permitted. Other variables available at the individ-
ual level in the local data were gender and birth date. Prior popu-
lation characterization has shown that the population captured by
the databases reflected the age and gender distribution in the
countries [19].
For each vaccine, we defined study cohorts by birth years. The
age at the start of follow-up was an additional inclusion criterion
for measles and HPV-vaccine coverage estimation. This inclusion
Table 1
Characteristics of the databases included in the fit-for-purpose.
Country Denmark Spain Italy United Kingdom
Name SSI/AUH BIFAP SIDIAP PEDIANET Val Padana THIN RCGP-RSC
Type of
organisation
providing
access
Different public
data holders
Spanish regulatory
agency
Public research
organisation
Private organisation;
vaccines from public
health
Local public health
agency
Academic
License
holder
(Erasmus
MC)
Charity
Origin of data Hospital discharge
diagnoses linked
to population and
vaccination
registries.
National health
care
Family
paediatricians and
general
practitioners
medical records
Family
paediatricians and
general
practitioners
medical records
Family paediatricians
medical records
linked to regional
vaccination register
Hospitalisation
discharge diagnoses
linked to population and
vaccination registries
General
practitioners
medical
records
General
practitioners
medical
records
Geographic
spread
National Multiregional:9
out of 17 regions
Catalonia Region Sample from Veneto
Region
Regional, province National
sample
National
sample
Table 2
Overview of the recommended age of vaccination by country and vaccine, data obtained from eCDC [20].
Country Databases 1e Measles 2e Measles 1e HPV Influenza recommended to persons > 65 years
Denmark SSI/AUH 15 m 4y 12y Yes
Italy PEDIANET – Val Padana 13–15 m 5-6y 12y Yes
Spain BIFAP – SIDIAP 12 m 3-4y 11-14y Yes
UK RCGP-RSC – THIN 12 m 3y 12-13y Yes
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was defined as unregistered vaccinations because follow-up had
not started at the time of vaccination. We estimated age-specific
measles-vaccine coverage for children born in 2006. Only children
who started follow-up before the age of 100 weeks were included
in the measles analysis. For the estimation of coverage with HPV-
vaccine, the study population comprised all female children born
between 1990 and 2000 who started follow-up before the age of
nine years. To estimate influenza-vaccine coverage in the elderly
(65 years and older) for the influenza seasons between 2009 and
2015, the study population comprised all persons born between
1920 and 1950.2.5. Distributed data processing
In the distributed approach, data access providers extracted and
transformed the data into the common data model (CDM) compris-
ing the individual-level vaccination and population files described
above. An R-script was sent to the data access providers. The R-
script conducted cleaning, application of inclusion and exclusion
criteria, data collection for the attrition tables, transformation
and coverage estimation. Cleaning of the study population con-
sisted of removing incomplete records, incorrect records (e.g. a
negative period of follow-up) and duplicates. Duplicated vaccina-
tion records were defined as having the ‘same dose, same vaccine
component’ and ‘same date, same vaccine component’. After link-
ing the population file to the vaccination file, vaccinations occur-
ring outside of an individual’s start- and end-date of follow-up
were censored. The attrition tables provided information on: the
number of persons by birth year and their time in follow-up, the
number of persons excluded because their age at the start of
follow-up exceeded the predefined limit, the number of vaccina-
tion records.
The tables that the R-script generated contained age-specific
coverage estimates by method, week of age, birth year, vaccine
component and dose. Bootstrapped 95% confidence intervals were
obtained for the measles-vaccine by sampling from the input-
records randomly with replacement. A total of 1000 samples weretaken for the calculation of each bootstrapped confidence interval.
Tables with aggregated data were shared to a remote research
environment through a secure file transfer protocol.
Central to our approach is that a single R-script was provided to
all databases. The script extracted and analysed the data available
for the previously described study populations. Not all databases
were able to provide all estimates. Pedianet could not provide
information on HPV-vaccine, since only birth years 2006 and
2007 were linked to vaccination registries, nor on influenza in
adults, as this is a paediatric database. Val Padana did not con-
tribute to the influenza-vaccine coverage estimation because the
birth years under investigation were not present in the database.
Several databases could not provide HPV-vaccine coverage esti-
mates for the birth years 1990–1993. THIN did not provide esti-
mates for the second dose measles vaccine. THIN and BIFAP did
not provide all seasonal influenza-vaccines estimates.
2.6. Coverage estimation
Coverage was estimated by birth year over age in weeks. For
example for persons born in 2006, we estimated the coverage with
the first dose measles-vaccine at 1 week of age, 2 weeks of age, etc.
Age in weeks was calculated as birthdatestudydate7 rounded down. The
number of persons in follow-up for at least one day during an
age in weeks was counted. We further counted the number of per-
sons who received a vaccination during that week, and those who
had a registered vaccination prior to that age in weeks. From these
counts we calculated two coverage estimates: a period prevalence
(PP:fui) estimate and an inverse probability weighted (IPW)
estimate.
The PP:fui for age in weeks i is estimated as:
PP:fui ¼
Nvaccinated&inFUi
NinFUi
With PP:fui: the coverage estimated by the PP:fu-method during
week i, Nvaccinated&inFUi the number of persons in follow-up dur-
ing week i who have been vaccinated prior to or during week and
NinFUi: the total number of persons in follow-up during week i.
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With FUproportion;i: the proportion of persons in follow-up during
week i, NinFUi: the total number of persons in follow-up during
week i and NinFU: the total number of persons in the birth cohort.
VaccIPW;i ¼ Vaccobserved;iFUproportion;i
With VaccIPW;i: the estimated number of vaccination during week i,
Vaccobserved;i: the observed number of vaccinations during week i and
FUproportion;i: the proportion of persons in follow-up during week i.
IPWi ¼
P
0!iVaccIPW;i
NinFU
With IPWi: the coverage estimated by the IPW-method during
week i, VaccIPW ;i: the estimated number of vaccination during week
i and NinFU: the total number of persons in the birth cohort.
A simple example to illustrate the method; when 50% of the
study cohort was in follow-up during age week 3 and 100 vaccina-
tions were registered during this week, we assumed that 200
vaccinations were administered at 3 weeks of age (100 regis-
tered + 100 censored).
The PP.fu-method relies on the assumption that the age-specific
coverage estimated from the part of the population in follow-up at
any age in weeks represent the age-specific coverage of the popu-
lation. The IPW-method relies on the assumption that the propor-
tion of persons in follow-up receiving a vaccine during a certain
age in weeks equals the proportion of persons not in follow-up
receiving a vaccine. Since this assumption is likely violated for
the influenza-vaccine study population, as in older age groups
death is a common cause of loss to follow-up, the IPW-method
was not applied to influenza-vaccine. A general summary of these
assumptions is that with the PP.fu-method we assumed that the
observed coverage equalled the study population coverage, while
with the IPW-method we estimated the coverage. Both methods
will deliver biased estimates when the probability of vaccination
differs in and out of follow-up.
3. Results
3.1. Measles-vaccine coverage
For measles-vaccine, the seven databases contributed a total of
362,063 persons born in 2006, of which 274,616 were eligible for
analysis. The exclusion of persons was due to entering the database
at an age older than 100 weeks (N = 87,447). A total of 401,094 vac-
cine doses (dose 1 and dose 2) were recorded for this study popu-
lation. The numbers by database can be found in the attrition
tables in the supplementary file.
Fig. 1 shows the proportion of persons in the study population
in follow-up from birth to seven years of age. The study population
in Pedianet that had consented to be linked to the vaccine registry
had complete follow-up. The proportion in follow-up in the
national SSI/AUH-databases remained high. In the regional Val
Padana and primary care databases the proportion of persons in
follow-up was more dynamic; the proportion of persons in
follow-up increased until the age-limit (100 weeks of age) set as
additional inclusion criterion. After which, the proportion of per-
sons in follow-up decreased. The decrease was substantially for
the BIFAP, RCGP-RSC and THIN-databases.
Fig. 2 shows the age-specific coverage estimates for the first and
second dose of measles-vaccines, using the PP.fu-method and the
IPW-method. Table 3 shows the estimates at seven years of age.
The start of uptake for the first dose of measles-vaccine ranged
from 0.6 years (SIDIAP) to 1.2 years of age (SSI/AUH). After theinitial steep increase in coverage at one year of age, THIN, RCGP-
RSC and SSI/AUH reported a continuing increase over time, repre-
senting vaccinations after the recommended age for vaccination. A
second increase was seen at the age of five years in the Val Padana-
database. At seven years, the IPW-estimate for the first dose ranged
from 96.5% (Val Padana) to 84.3% (SSI/AUH).
For the second dose of the measles-vaccine only RCGP-RSC
reached a coverage of 90% (IPW-estimate). The increase in cover-
age over age was less steep, stepwise for some databases, and
the attained coverage for the second dose was below the coverage
attained for the first dose. The minimum difference between the
first and second dose coverage was 1.5% (BIFAP), the maximum dif-
ference was 13.7% (Val Padana). There were differences between
countries with respect to the age at which the coverage with the
second dose started increasing. For SIDIAP, a second dose coverage
of around 30% was reached at the age of two years. At seven years
the IPW-estimate for the second dose ranged from 90.9% (RCGP-
RSC) to 80.0% (SSI/AUH).
3.2. HPV-vaccine coverage
The HPV study population of females born between 1990 and
2000 with follow-up before the age of nine years comprised
2,011,666 persons. The total number of first dose recorded HPV-
vaccine registrations for the study population was 838,823. Several
of the databases did not contribute to the birth cohorts from 1990
to 1993. For the 1990 birth cohorts to be included, the databases
needed to have started follow-up by 1999 (because the ‘age at start
of follow-up’-inclusion criterion was set at nine years) and this
information needed to be present in the input-files. An overview
of the study population by database can be found in the attrition
tables in the supplementary file.
The age at the start of HPV-vaccination differed between data-
bases as did the coverage attained at the age of 15 years. E.g. in
the UK (THIN & RCGP-RSC) HPV-vaccination started one birth year
later than in Denmark (SSI/AUH) and Spain (BIFAP). SSI/AUH
attained a HPV-vaccine coverage of >70% for birth year 1994 after
which the coverage continued to increase. The other databases,
except for RCGP-RSC and THIN, also reported an increasing cover-
age over the birth years included in this study. The attained HPV-
vaccine first dose coverage at the age of 15 years for females born
between 1997 and 2000 estimated with the IPW-method ranged
between 60% (RCGP-RSC/THIN) and 88.3% (SSI/AUH) (Table 4)
(Fig. 3). A figure with PP.fu-estimates is provided in the supple-
mentary file.
3.3. Influenza-vaccine coverage
Five databases captured information on influenza-vaccines in
the elderly. The number of persons included in the estimation
increased from 3,686,640 persons for the influenza season 2009–
2010 to 4,932,582 for the influenza season 2014–2015. A figure
of the proportion of persons in follow-up per database per season
and the attrition tables are provided in the supplementary file.
There were large between databases differences in the attained
coverage. SSI/AUH reported coverages between 40 and 45% for all
seasons, while THIN and RCGP-RSC reported coverages around
70%. There was a downward trend in coverage in recent seasons
in the SIDIAP-database (from 58% in 2009/10 to 50% coverage in
2013/14 seasons). The other databases showed no clear time-
trend in estimated coverage from the 2009–2010 season to the
2014–2015 season (Fig. 4).
Influenza-vaccine coverage increased with age for persons aged
65 years and more. The increase was followed by a decline in the
oldest age groups. In the UK (RCGP-RSC and THIN) the highest cov-
erage was reached in persons aged 77–80 years. In Spain (BIFAP
Fig. 1. Proportion of persons in follow-up, with start of follow-up before the age of 100 weeks and birth year 2006 over age in years, by database.
T. Braeye et al. / Vaccine 38 (2020) 3243–3254 3247and SIDIAP) and Denmark (SSI/AUH) the highest coverage was
reached at a later age, around 85–87 years. This pattern was seen
over all studied influenza seasons. Due to the low number of per-
sons in follow-up in the oldest age groups, the PP.fu-estimate
became unstable (Fig. 5).4. Discussion
This study aimed to assess part of the suitability of eHR-
databases to participate in distributed vaccine studies. We also
aimed to test the broad use of a common data model and a com-
mon analysis script. We found that, given that the data were avail-
able, age-specific, but also calendar year or season-specific
coverage estimates could be obtained through this common proce-
dure. Limitations however exist, both with respect to methods for
coverage estimation and the estimates obtained.4.1. Methods for coverage estimation
Previous research has pointed to the importance of both the
total uptake and the timeliness [21]. We therefore selected two
methods that allowed for age-specific estimates and could repre-
sent vaccinations before and after the recommended age at vacci-
nation. Since left and right censoring because of incomplete follow-
up were present in different proportions in several of the data-
bases, the methods also had to be able to account for censored
events. Censoring was especially present in databases linked togeneral practice. The PP.fu- and IPW-method accounted for censor-
ing in different ways. PP.fu and IPW-estimates were comparable
when incompleteness in follow-up was limited. As there was no
loss to follow-up in the Pedianet-database, the IPW and
PP.fu-estimates were equal. The absence of incomplete follow-up
in the Pedianet database is an artefact of the need to ask for con-
sent to be linked to the immunization registry. Consent was only
obtained for persons still registered in 2015 and born in 2006
and 2007.
A limitation of the PP.fu-method was the inability to account for
left censoring; entering the database after vaccination caused
underestimation [22,23]. As we had set the inclusion criterion for
the first dose of measles-vaccine at a starting age of follow-up of
100 weeks (an age at which most children had already received a
first dose of measles-vaccine) and because follow-up was dynamic
in some databases, left censoring was likely. As a result, the PP.fu-
estimates for the first dose of measles-vaccine were lower than the
IPW-estimates for some databases. As incompleteness increased,
the difference between IPW and PP.fu-estimates became larger. It
was largest for the THIN and BIFAP-database. If the ‘age at the start
of follow-up’-inclusion criterion was set before the recommended
age of vaccination, it could avoid most left-censoring and therefore
underestimation by the PP.fu-method. This happened for both the
second dose of measles-vaccine and for the first dose of HPV-
vaccine. Overall, an ‘age at the start of follow-up’-inclusion crite-
rion can reduce left censoring, but it will also reduce the study
population to a smaller sample and that sample might no longer
be representative for the total population. This criterion and the
Fig. 2. Coverage with measles-vaccine by age. A: first dose, PP.fu-estimate, B: first dose, IPW-estimate, C: second dose, PP.fu-estimate, D: second dose, IPW-estimate over age
in years by database for measles-vaccine, birth year 2006.
Table 3
Measles coverage estimates for the first and second dose at seven years of age and bootstrapped 95% confidence interval.
Country Database First dose measles at age 7 years Second dose measles at age 7 years
PP.fu-estimate IPW-estimate PP.fu-estimate IPW-estimate
Italy Val Padana 96.1% (95.6–97.2%) 96.5% (95.8–97.9%) 83.8% (83.3–85.3%) 82.8% (82.3–84.3%)
Pedianet 92.4% (92–93.2%) 92.4% (92–93.2%) 86% (85.3–87%) 86% (85.3–87%)
Spain BIFAP 90% (89.5–90.5%) 89.3% (88.9–89.5%) 91.9% (91.6–92.1%) 87.8% (87.5–88%)
SIDIAP 92.1% (91.7–92.3%) 94% (94–95.2%) 90.1% (89.5–90.6%) 88.3% (84.6–85.4%)
UK RCGP-RSC 92.3% (91.6–93%) 95.2% (94.5–95.9%) 93.1% (92.3–93.9%) 90.9% (90.1–91.7%)
THIN 91.5% (91.2–91.7%) 94.1% (93.8–94.3%) / /
Denmark SSI/AUH 85.2% (85–85.5%) 84.3% (84.1–84.5%) 80.4% (80.1–80.6%) 80.0% (79.7–80.2%)
Table 4
HPV-vaccine, first dose coverage estimates (IPW & PP.fu-method) at the age of
15 years aggregated over birth years 1997–2000, females.
Country Database PP.fu-estimate IPW-estimate
Italy Val Padana 73.7% 75.8%
Spain BIFAP 78.8% 86.9%
SIDIAP 77.5% 77.0%
UK RCGP-RSC 56.2% 60.0%
THIN 57.8% 60.0%
Denmark SSI/AUH 88.6% 88.3%
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esting topics for further research.
The IPW-method accounts for both left and right censoring of
vaccinations, but can produce unstable estimates when weightsare very small or large and bias can accumulate as the method
sums over the weekly estimated number of vaccinations. In the
BIFAP-database the large difference between the IPW (86.9%) and
PP.fu (78.8%)-estimates for the first HPV-vaccine dose was likely
caused by the high proportion of incomplete follow-up (<50%) over
a longer time period. In such instances the PP.fu-estimates might
be preferred.
We recommend to always present and describe the incomplete-
ness of the databases and to apply several methods. Large differ-
ences between methods can indicate left censoring, unstable
estimation because of little data or a violation of the assumption
of an equal age-specific probability of vaccination in and out of
follow-up. An unequal vaccination probability in and out of
follow-up will bias both methods, but it will result in a bias that
Fig. 3. A: proportion of females in follow-up at the age of 12 years over birth years by database, B: HPV-vaccine, first dose coverage estimates at 15 years (IPW-method) over
birth years (1990–2000) by database, C: age-specific first dose HPV-vaccine coverage estimates (IPW-method) over age by database, birth years 1997–2000.
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Fig. 4. Influenza-vaccine coverage estimates (PP.fu-method) for those aged over 65 years over influenza season by database, birth years 1920–1950, influenza seasons 2010–
2015.
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IPW-method (as the estimated number of vaccines at ‘age in
weeks’ t  1,t  2,. . . is used for estimating the coverage at ‘age in
week’ t), while it will bias the PP.fu-estimates for each ‘age in
week’-estimate independently. It is therefore likely to result in a
larger bias for the IPW-method (this can be further explored in
our corresponding simulation study [17]).
We only accounted for censoring because of incomplete follow-
up. We assumed no incorrect or missing registration during follow-
up. Previous studies have shown that the presence of a vaccination
record in an electronic database reliably indicates immunization
while the absence of such a record can be inaccurate [24]. This
therefore was a strong assumption; e.g. vaccinations may be
administered by non-traditional providers who were not affiliated
with the database [4,25].
4.2. Comparison to published coverage estimates
Researchers have been concerned with the validity and compa-
rability of coverage estimates over different studies, areas and time
[35]. As methodological differences and differences in data source
have proven to be relevant [3,36], they should be taken into con-
sideration when comparing our estimates to previously published
estimates. We first considered the reported outcome; our esti-
mates were reported as age-specific estimates by birth year. Other
research might report point estimates for age groups by calendar
year. In addition to the heterogeneity in outcomes, we anticipated
other methodological differences. Our methodology was designed
specifically to account for the dynamic follow-up of populations
in eHR-databases. While survival methods have been applied in
coverage estimation to investigate timeliness of vaccine uptakeand right-censoring [37], accounting for both left- and right-
censoring is, to our knowledge, unique to this work. Finally, differ-
ences in coverage estimation can be linked to the source of the
data. For example, the databases linked to primary care from cer-
tain regions might not be representative for the national level. In
addition, we added an inclusion criteria to some of our examples,
possibly further limiting the comparability of our estimates to pre-
viously published estimates. Therefore, while we anticipated some
differences, we also expected them to have multiple causes and it
was unclear what the clinical significance (i.e., the magnitude of
impact) of these differences was [36]. An individual assessment
for all vaccines by database was necessary.
In recent years several measles outbreaks have been reported
in the European Region associated to immunity gaps; pockets of
unvaccinated children and adults [38]. From the four countries
in this study, Spain was the only country with a coverage over
95% for the first dose, none obtained a coverage over 95% for
the second dose. The IPW-estimates for the first dose of
measles-vaccine were both below (2–8% Denmark and Spain)
and above (2–9% UK and Italy) previously published national esti-
mates (Table 5). For the second dose, our estimates were gener-
ally below (3–5%) previously published national estimates. We
observed some issues with the dose of measles-vaccines in Val
Padana. A sudden increase in first dose coverage sometime after
the recommended age of vaccination probably reflected wrongly
coding the second dose as the first. Val Padana showed the high-
est coverage with the first dose of measles and the lowest with
the second dose. The first dose coverage increased suddenly at
age 5, which is the recommended age for the second dose. The
Val Padana database did not register the dose at administration
but derived it afterwards from the sequence of observed vaccina-
Fig. 5. Influenza-vaccine coverage (PP.fu-method) over age in years by season, (A) RCGP-RSC, (B) SSI/AUH, (C) SIDIAP, birth years 1920–1950, influenza seasons in 2009–2015.
T. Braeye et al. / Vaccine 38 (2020) 3243–3254 3251tions. We observed differences between databases from the same
country: for the measles-vaccine we observed a 1–2% difference
between SIDIAP and BIFAP (Spain) and 3–4% between Pedianet
and Val Padana (Italy). The differences were small given that they
collected data from different regions. In 2006 an unprecedented
outbreak occurred in Catalonia, Spain, affecting mostly young
children (<16 months) [39]. This resulted in an early administra-
tion of the first dose of measles vaccine, before the age of one
year, followed by an early administration of the second measles
dose, by the age of 12–15 months. This explained the 30% second
dose coverage at around 15 months followed by the, anticipated,
second increase in coverage at 4 years.
Since 2007 (HPV-vaccine was licensed in 2006), HPV-
vaccination has been implemented in Western-Europe. The tar-
geted population typically consists of girls aged 10–14 years. Sev-
eral modelling studies have suggested coverage levels at which
HPV serotypes can be eradicated ranging from 30 to 66% to 86–
94% depending on the serotype [40]. In 2014, the overall coverage
of the first dose of HPV in the European region was estimated at
49.6% (95% CI 40–54%) for females aged 10–20 [12]. The four coun-
tries included in this study had previously reported high coverages
(74–91%) [26–28], but estimates are known to vary over different
birth cohorts in the same country. For example, in Denmark a sig-
nificant decrease has been reported: a first dose coverage of 81%
was reported for girls born in 2002, the coverage decreased to
54% for girls born in 2003 and continued to decrease for later birth
years [30]. Our estimates are in general in agreement (+-5%) withpreviously published estimates except for the UK estimates. Offi-
cial UK HPV-vaccine coverage estimates for the first dose have
been around 85% since 2006. We however found a lower estimate
of 60% that was consistent over time for both databases. The most
likely explanation is that HPV-vaccination is not always provided
by the GP, since it is routinely offered in schools to girls aged 12
to 13 years. The BIFAP database recently conducted a study to val-
idate their HPV-vaccination data quality and confirmed that BIFAP
was ‘a potential data source for HPV vaccine research’ [41]. They
reported region-specific coverage between 70.6 and 99.8% for birth
cohorts born between 2000 and 2002, which included the 78.8%
obtained in this study [42].
Previous research reported that influenza-vaccine coverage has
been low in persons aged 65 years and more. Only a few countries,
among which the UK, had achieved 75% coverage in the period
2009–2011 [33]. Influenza-vaccine coverage was estimated at
58.6% in the 2010–2011 season and 62.7% in the 2009–2010 season
in persons aged 65 years and more in Navarre, Spain. In the 2012–
2013 season the coverage in Madrid was estimated at 56.6% in per-
sons aged 65 years and more [43]. Our influenza estimates by sea-
son were below (2–7%) these previously published estimates for all
databases, but showed comparable time trends. Our results on
influenza coverage by age agreed with previous research and pre-
sented the age-group from 77 to 94 years as the age-group with
the highest coverage.
There are several limitations associated with our approach. First
the creation of the input-files was a database-specific process. The
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3252 T. Braeye et al. / Vaccine 38 (2020) 3243–3254process from original data to data in the common data model,
included steps of data cleaning, handling missing data, removing
duplicates, which were imperfectly documented and likely differed
between databases. As a consequence, some of the differences
within and between databases (e.g. changes in data collection over
time) and with published national estimates could not be fully
explored. Future studies should further explore these differences.
These studies will require participation by the data access provider
(input-file creation and access) and a thorough understanding of
the R-scripts used for data transformation and analysis. In addition,
there should also be a detailed insight into how the reference esti-
mates were calculated.
Second, closely related to the first point, dose derivation in the
absence of a recorded dose, would ideally be part of the common
procedure. Given the current absence of guidelines for deriving a
dose number, it is unclear how best to approach this. Third, in this
paper the exact vaccines are not specified. Influenza-vaccine might
for example represent a trivalent or a quadrivalent vaccine. The
within-database coding of such vaccine specifications might differ
between databases. Finally, we did not look into coverage with a
sequence of vaccines. We reported coverage with the first and cov-
erage with the second dose of measles-vaccine, but not coverage
with both doses. Likewise for the influenza-vaccine we could not
identify the proportion of persons vaccinated during, for example,
both the influenza seasons 2010/11 and 2011/12.5. Conclusion
As part of a fit for purpose assessment we estimated the vacci-
nation coverage for measles, HPV and influenza-vaccines in seven
European eHR databases. The distributed approach, with a com-
mon data model and common analysis, was feasible for all partic-
ipating databases. The similar way in which the age-specific
coverage is estimated, facilitates further use in international vac-
cine studies. The comparison with published reference coverage
estimates showed validity of our procedure and the reliability of
eHR-databases as source for coverage estimation, but an individual
database-specific assessment of the results remains essential.CRediT authorship contribution statement
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